The underlying clinical trial, registered as NCT05597020, enrolled 60 adults aged 55 or older who had endured insomnia symptoms for at least three months, scored 13 or higher on the Insomnia Severity Index, and reported at least three nocturnal voids per night. Participants were randomized in a one-to-one ratio to receive either daridorexant 50 mg or placebo for four weeks, then crossed over to the other treatment after a washout period of 14 to 21 days. This crossover design carries a distinct methodological advantage: each participant serves as their own control, which minimizes inter-participant variability and allows direct within-person comparisons of how the two treatments felt in everyday life.

What makes the new publication unusual is its commitment to the qualitative dimension of the patient experience. Alongside the validated questionnaires that formed the trial’s quantitative backbone, patients were asked open-ended, free-text questions at baseline and at the end of each treatment period. At screening, they described how insomnia and nocturia had impacted their daily lives before the study began. After each treatment month, they were asked how that impact had changed while taking the study medication. The replies were pooled into two groups, one containing responses from patients who had received daridorexant during either treatment period and the other containing responses from patients who had received placebo, and the analysis team remained blinded to treatment assignment until the coding was complete.

The analytic machinery behind the study was deliberately rigorous. Using MAXQDA version 2024, a qualitative data analysis platform, a trained analyst coded every response according to a structured codebook developed under a predefined Qualitative Analysis Plan. The codebook captured mentions of sleep, nocturia, and their impacts on physical, emotional, and cognitive functioning, activities of daily living, professional life, and relationships, with sub-codes recording whether patients described improvement, stability, worsening, or mixed change. Crucially, the themes emerged inductively from the data rather than being imposed by prior hypotheses, and no automated or AI-assisted coding was used. Regular meetings between the analyst, the research lead, and a scientific advisor resolved ambiguities, and all analytic decisions were logged to maintain consistency across the dataset.

The baseline picture that emerged was bleak and remarkably consistent. Of the 59 patients who replied at baseline, 68 percent described sleep problems, including difficulty falling asleep, staying asleep, and waking too early, while 37 percent described nocturia symptoms such as frequent nighttime voiding or incontinence. Two-thirds of replies referenced sleep issues and one-third referenced nocturia, suggesting that for these patients the insomnia itself was the more bothersome burden. But the damage extended far beyond the bedroom. Fully 83 percent of respondents commented on impacts on their lives, with 61 percent reporting negative effects on physical functioning, citing fatigue, tiredness, low energy, weakness, dizziness, and grogginess, and 52.5 percent reporting emotional tolls including frustration, irritability, stress, and nervousness. One in five described impaired cognition, and work and social life suffered as well.

After four weeks on treatment, the contrast between daridorexant and placebo was striking. Among patients taking daridorexant, 87 percent reported improvement in their sleep, compared with just 50 percent on placebo, a difference the researchers found highly significant with a p value of 0.0011. Only 10 percent of daridorexant patients said their sleep problems were unchanged, versus 40 percent of placebo patients. The nocturia findings were, if anything, more dramatic: 79 percent of patients on daridorexant reported improvement in their nighttime voiding, compared with 32 percent on placebo, a highly significant difference with a p value of 0.0013. These patient-perceived improvements align closely with the trial’s quantitative results, which showed that daridorexant increased subjective total sleep time by roughly 21 minutes and reduced nocturnal voids by an average of 1.5 episodes per night.

The benefits rippled outward into daily functioning. Improvements in quality-of-life impacts were reported by 73.7 percent of daridorexant patients who commented on impacts, compared with 46.7 percent of placebo patients. Physical functioning showed the largest gains, with 52.6 percent of daridorexant patients reporting improvement versus 26.7 percent on placebo. Cognitive functioning, activities of daily living, and emotional functioning also improved more frequently under daridorexant, with placebo patients showing no reported cognitive improvements at all. Patients described feeling less fatigued, more able to concentrate, and better equipped to manage ordinary routines that fragmented sleep had made exhausting.

Why would a sleep drug ease the urge to urinate at night? The authors offer two complementary hypotheses. The first is mechanical: by lengthening sleep duration and shortening long awakenings, daridorexant simply gives patients fewer opportunities to notice a full bladder, an explanation supported by earlier work showing that behavioral treatment of insomnia alone reduced self-reported nocturnal voids in older adults. The second is neurobiological and arguably more intriguing. The orexin system, best known for stabilizing wakefulness, also appears to influence micturition. Animal studies have shown that orexin-A activates the micturition reflex, and that blocking orexin 2 receptors restores abnormal bladder markers in models of overactive bladder. In humans, orexin antagonists may increase bladder capacity by prolonging the interval between bladder contractions. Consistent with this, orexin agonists given to people with narcolepsy have produced increased urinary urgency and frequency as expected on-target effects, the mirror image of what antagonists appear to do.

The study’s authors argue that these findings fill a genuine gap in sleep medicine. A systematic review of qualitative insomnia research identified only 22 published studies, many of which actually relied on quantitative methods, and concluded that well-conducted qualitative work in the field remains scarce compared with areas such as depression. Free-text responses complement structured patient-reported outcome measures by adding contextual depth, capturing experiences such as non-restorative sleep and mood disturbance that objective measures may miss. The longitudinal design of the survey, with baseline responses collected before treatment, also avoids the recall bias inherent in asking patients at study exit to reconstruct how they felt months earlier. And because patients were blinded to treatment and the analysts were blinded too, expectancy effects were constrained as far as the design allows.

Limitations remain, and the authors are candid about them. Responses summarized an entire month retrospectively, inviting recall bias, and the level of detail varied considerably across patients. A few replies were missing or uninterpretable, and subjective free-text data can still be shaped by placebo and expectancy effects even in a blinded crossover. Coding inevitably involves some interpretive judgment, mitigated here by a predefined analysis plan, blinded coding, and documented quality checks. The study also relied on patient history rather than polysomnography to exclude other sleep disorders. Even so, the message is compelling: patients with moderate to severe insomnia and clinically meaningful nocturia reported broad damage to their physical, emotional, and cognitive lives, and daridorexant 50 mg consistently elicited more positive patient-reported change than placebo across sleep, voiding, and daily functioning. As clinical trials increasingly seek to center the patient’s voice, this study offers a template for letting patients describe, in their own words, what treatment actually feels like.

Subject of Research: Qualitative patient-reported outcomes of daridorexant treatment in adults with chronic insomnia and comorbid nocturia

Article Title: Capturing the Patient Voice: Qualitative Assessment of Daridorexant’s Impact on Patients with Insomnia and Comorbid Nocturia from a Randomized, Placebo-Controlled Crossover Trial

Article References: Arnaldi, D., Bliwise, D. L., Alpan, D., Koochaki, P., Meinel, M., Olivieri, A., Rowles, R., Satapathy, A., & Lederer, K. (2026). Capturing the Patient Voice: Qualitative Assessment of Daridorexant’s Impact on Patients with Insomnia and Comorbid Nocturia from a Randomized, Placebo-Controlled Crossover Trial. Advances in Therapy. https://doi.org/10.1007/s12325-026-03803-0

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03803-0

Keywords: daridorexant, insomnia, nocturia, dual orexin receptor antagonist, patient-reported outcomes, qualitative research, crossover trial, sleep medicine, quality of life, orexin system, placebo-controlled trial, daytime functioning